Dr. McKay Discusses Advances in the Treatment of Metastatic RCC

Rana R. McKay, MD
Published: Thursday, Jan 04, 2018



Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).

One of the most influential studies over the past few years has been the CheckMate-025 study in patients with metastatic clear cell RCC, says McKay. This was the first time that a second-line treatment was shown to improve overall survival in this population.

Studies with cabozantinib (Cabometyx), ipilimumab (Yervoy) plus nivolumab (Opdivo), and sunitinib (Sutent) have also enriched the treatment landscape of metastatic RCC, McKay adds.
 
SELECTED
LANGUAGE


Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).

One of the most influential studies over the past few years has been the CheckMate-025 study in patients with metastatic clear cell RCC, says McKay. This was the first time that a second-line treatment was shown to improve overall survival in this population.

Studies with cabozantinib (Cabometyx), ipilimumab (Yervoy) plus nivolumab (Opdivo), and sunitinib (Sutent) have also enriched the treatment landscape of metastatic RCC, McKay adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x